Biogen Idec, Elan release data on safety of Tysarbi
CAMBRIDGE, Mass. Biogen Idec and Elan have announced that they have new data on the global utilization and safety of Tysarbi, which states that as of the end of September about 17,000 patients were on a commercial and clinical therapy, and that the safety data continue to support the drug,
Tysarbi is a treatment for relapsing forms of multiple sclerosis in the U.S. and for relapsing-remitting multiple sclerosis in the European Union. The drug is available stateside through the Tysarbi Outreach Unified Commitment to Health, in which patients enroll to be able to take the drug.
Another program used to keep track of patient information is, the Tysarbi Global ObseRvation Program In Safety, which works in part with TOUCH.